Literature DB >> 23356950

Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia.

Dan Shan1, Elizabeth K Lucas, Jana B Drummond, Vahram Haroutunian, James H Meador-Woodruff, Robert E McCullumsmith.   

Abstract

Glutamate transporters facilitate the buffering, clearance and cycling of glutamate and play an important role in maintaining synaptic and extrasynaptic glutamate levels. Alterations in glutamate transporter expression may lead to abnormal glutamate neurotransmission contributing to the pathophysiology of schizophrenia. In addition, alterations in the architecture of the superior temporal gyrus and hippocampus have been implicated in this illness, suggesting that synapses in these regions may be remodeled from a lifetime of severe mental illness and antipsychotic treatment. Thus, we hypothesize that glutamate neurotransmission may be abnormal in the superior temporal gyrus and hippocampus in schizophrenia. To test this hypothesis, we examined protein expression of excitatory amino acid transporter 1-3 and vesicular glutamate transporter 1 and 2 in subjects with schizophrenia (n=23) and a comparison group (n=27). We found decreased expression of EAAT1 and EAAT2 protein in the superior temporal gyrus, and decreased EAAT2 protein in the hippocampus in schizophrenia. We didn't find any changes in expression of the neuronal transporter EAAT3 or the presynaptic vesicular glutamate transporters VGLUT1-2. In addition, we did not detect an effect of antipsychotic medication on expression of EAAT1 and EAAT2 proteins in the temporal association cortex or hippocampus in rats treated with haloperidol for 9 months. Our findings suggest that buffering and reuptake, but not presynaptic release, of glutamate is altered in glutamate synapses in the temporal lobe in schizophrenia.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23356950      PMCID: PMC3572263          DOI: 10.1016/j.schres.2012.12.019

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  81 in total

Review 1.  Glutamate receptors and transporters in the hippocampus in schizophrenia.

Authors:  Paul J Harrison; Amanda J Law; Sharon L Eastwood
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

Review 2.  Glutamate transporters: confining runaway excitation by shaping synaptic transmission.

Authors:  Anastassios V Tzingounis; Jacques I Wadiche
Journal:  Nat Rev Neurosci       Date:  2007-12       Impact factor: 34.870

3.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

Authors:  B Moghaddam; B W Adams
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

4.  Distribution of glutamate transporter subtypes during human brain development.

Authors:  O Bar-Peled; H Ben-Hur; A Biegon; Y Groner; S Dewhurst; A Furuta; J D Rothstein
Journal:  J Neurochem       Date:  1997-12       Impact factor: 5.372

5.  Cell loss in the hippocampus of schizophrenics.

Authors:  P Falkai; B Bogerts
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986

6.  Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate.

Authors:  J D Rothstein; M Dykes-Hoberg; C A Pardo; L A Bristol; L Jin; R W Kuncl; Y Kanai; M A Hediger; Y Wang; J P Schielke; D F Welty
Journal:  Neuron       Date:  1996-03       Impact factor: 17.173

7.  Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons.

Authors:  S Takamori; J S Rhee; C Rosenmund; R Jahn
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

Review 8.  The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia.

Authors:  Kuei Y Tseng; R Andrew Chambers; Barbara K Lipska
Journal:  Behav Brain Res       Date:  2008-12-03       Impact factor: 3.332

9.  Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium.

Authors:  Natalya A Uranova; Victor M Vostrikov; Diana D Orlovskaya; Valentina I Rachmanova
Journal:  Schizophr Res       Date:  2004-04-01       Impact factor: 4.939

10.  The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine.

Authors:  M Melone; L Vitellaro-Zuccarello; A Vallejo-Illarramendi; A Pérez-Samartin; C Matute; A Cozzi; D E Pellegrini-Giampietro; J D Rothstein; F Conti
Journal:  Mol Psychiatry       Date:  2001-07       Impact factor: 15.992

View more
  36 in total

Review 1.  Translational potential of astrocytes in brain disorders.

Authors:  Alexei Verkhratsky; Luca Steardo; Vladimir Parpura; Vedrana Montana
Journal:  Prog Neurobiol       Date:  2015-09-16       Impact factor: 11.685

2.  The infralimbic cortex bidirectionally modulates mesolimbic dopamine neuron activity via distinct neural pathways.

Authors:  Mary H Patton; Brandon T Bizup; Anthony A Grace
Journal:  J Neurosci       Date:  2013-10-23       Impact factor: 6.167

3.  Abnormal partitioning of hexokinase 1 suggests disruption of a glutamate transport protein complex in schizophrenia.

Authors:  Dan Shan; Daniel Mount; Stephen Moore; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2014-02-21       Impact factor: 4.939

Review 4.  GLAST But Not Least--Distribution, Function, Genetics and Epigenetics of L-Glutamate Transport in Brain--Focus on GLAST/EAAT1.

Authors:  Omar Šerý; Nilufa Sultana; Mohammed Abul Kashem; David V Pow; Vladimir J Balcar
Journal:  Neurochem Res       Date:  2015-05-14       Impact factor: 3.996

5.  Localization of excitatory amino acid transporters EAAT1 and EAAT2 in human postmortem cortex: a light and electron microscopic study.

Authors:  R C Roberts; J K Roche; R E McCullumsmith
Journal:  Neuroscience       Date:  2014-07-24       Impact factor: 3.590

6.  Altered serine/threonine kinase activity in schizophrenia.

Authors:  Jennifer L McGuire; John H Hammond; Stefani D Yates; Dongquan Chen; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Brain Res       Date:  2014-04-26       Impact factor: 3.252

Review 7.  The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.

Authors:  Wei Hu; Matthew L MacDonald; Daniel E Elswick; Robert A Sweet
Journal:  Ann N Y Acad Sci       Date:  2014-10-14       Impact factor: 5.691

Review 8.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

9.  Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia.

Authors:  Parisa Afshari; Marina Myles-Worsley; Ori S Cohen; Josepha Tiobech; Stephen V Faraone; William Byerley; Frank A Middleton
Journal:  Mol Neuropsychiatry       Date:  2015-07-08

Review 10.  Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.

Authors:  Ebrahim Haroon; Andrew H Miller; Gerard Sanacora
Journal:  Neuropsychopharmacology       Date:  2016-09-15       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.